Impact of abciximab and coronary stenting on outcomes and costs of percutaneous coronary interventions in a community hospital

Coronary Artery Disease

Volumn 12, Issue 2, 2001, Pages 135-142

  Lucore, Charles L ^a,b   Trask, Robert V ^a   Mishkel, Gregory J ^a   Rocha Singh, Krishna J ^a   Shelton, Marc E ^a   Mikell, Frank L ^a   Ligon, Robert W ^a  

^a Prairie Education and Research Cooperative   (United States)

^b Prairie Cardiovascular Consultants Ltd   (United States)

Author keywords

Abciximab; Community hospital; Coronary stent; Cost effectiveness; Glycoprotein IIb IIIa inhibitor; Myocardial infarction; Percutaneous coronary intervention; Unstable angina

Indexed keywords

ABCIXIMAB;

ARTICLE; COMMUNITY HOSPITAL; CORONARY RISK; CORONARY STENT; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEATH; DRUG COST; HEALTH CARE COST; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; FEMALE; HOSPITAL COSTS; HOSPITALS, COMMUNITY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REGRESSION ANALYSIS; STENTS; TREATMENT OUTCOME;

EID: 0035107597     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200103000-00007     Document Type: Article

References (23)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
3. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
4. Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
5. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
6. 3 blockade with percutaneous coronary intervention
7. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
8. The stentor and the sea change
9. The EPISTENT trial at 6 months: Relative and combined effects of abciximab and stenting on reduction of acute ischemic events and late revascularization
10. Economic issues in glycoprotein IIb/IIIa receptor therapy
11. Economic considerations in the use of the platelet glycoprotein inhibitor abciximab in percutaneous coronary intervention
12. Implications of IIb/IIIa receptor blockade for acute coronary syndromes in a community hospital
13. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty
14. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade during coronary intervention in the EPILOG trial [abstract]
15. Cost and outcomes analysis of abciximab use in a community teaching hospital
16. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3) among patients with unstable angina undergoing percutaneous coronary revascularization
17. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease
18. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
19. BENESTENT-II trial: Subgroup analysis of patients assigned either to angiographic and clinical follow-up or clinical follow-up alone
20. Effectiveness and cost-effectiveness of single bolus treatment with abciximab (ReoPro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients
21. Platelet GPIIb-IIIa blockers
22. Relationship of clinical variables to hospital cost for coronary interventions: A univariate and multivariate analysis